Abstract:Abstract Background: Responsiveness or ignorance of antigens presented to naïve T cells by dendritic cells (DC) involves the CD28-driven “signal 2”, but it is unclear how activated CTLs respond to the same non-mutated tumor-associated antigens (TAAs) presented by cancer versus healthy cells to avoid autoimmunity. Since CD8+ T cells express activating NK receptors (NKRs) and NKR ligands are commonly expressed by cancer cells but not healthy tissues, we evaluated the crosstalk between NKRs and TCR during recognition of cancer cells by DC-primed TAA-specific CTLs. Methods: Associations between DNAM-1, NKG2D, CTL markers, and patients’ survival was analyzed using TCGA. In vitro sensitization was used to induce human TAA-specific CTLs by TAA-loaded DCs. The roles of DNAM-1 and NKG2D in CTL recognition and killing were tested using IFN-γ ELISpot, conjugate formation, degranulation, and cytotoxicity assays. The mechanisms and molecular effects of NKR-mediated costimulation were analyzed using IsoPlexis, calcium flux, western blot, and RNA sequencing. Double-transduction of T cells with TCR and NKR constructs or pre-treatment of cancer cells by chemotherapy was used to manipulate the levels of NKRs on T cells or their ligands on cancer cells. Results: TCGA analysis revealed that DNAM-1 and NKG2D are strongly associated with intratumoral CD8+ T cells rather than NK cells, being critical for the long-term survival of melanoma patients. Human DC-primed CTLs significantly upregulated DNAM-1 and NKG2D compared to naïve CD8+ T cells, but retained strict dependence on TCR in cancer cell recognition. Unexpectedly, blockade of DNAM-1 and NKG2D prevented the TCR-mediated CTL recognition and killing of cancer cells expressing low-TAA levels, but were redundant in the recognition of high-TAA-expressing cancer cells. DNAM-1, and to a lesser extent NKG2D, lowered TCR activation threshold and enhanced proximal TCR signaling and CTL polyfunctionality. NKR overexpression in TCR-transgenic T cells or chemotherapy-driven elevation of NKR ligands on cancer cells allowed effective recognition and killing of weakly immunogenic cancer cells. Conclusions: Reduced TCR activation threshold in the presence of NKR costimulation enables CTL activation by low levels of cognate MHC I-peptide complexes on cancer cells. Our data helps explain the ability of non-mutated “self” antigens to mediate tumor rejection in the absence of autoimmunity, and provides new tools to enhance the effectiveness of cancer therapies. Citation Format: Bowen Dong, Nataša Obermajer, Takemasa Tsuji, Junko Matsuzaki, Cindy Bonura, Henry Withers, Mark Long, Colin Chavel, Scott H. Olejniczak, Hans Minderman, Robert P. Edwards, Walter J. Storkus, Pedro Romero, Pawel Kalinski. NK receptors enable TCR-mediated CTL recognition and killing of cancer cells expressing non-mutated tumor-associated antigens [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3966.

Mechanisms of NKT Cell Anergy Induction Involve Cbl-b-promoted Monoubiquitination of CARMA1

The Ire1 Endoplasmic Reticulum Stress Sensor Activates Natural Killer Cell Immunity And Promotes Natural Killer Cell Memory By Regulating C-Myc And Mitochondrial Respiration

Regulation of Activated Cd4(+) T Cells by Nk Cells Via the Qa-1-Nkg2a Inhibitory Pathway

Mechanisms of Cbl-Mediated Ubiquitination of Proteins in T and Natural Killer Cells and Effects on Immune Cell Functions

Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction.

NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention

Definition of a Qa-1-Qdm-dependent Interaction Between NK Cells and Activated T Cells That Inhibits Expansion and Memory Development of Pathogenic T Cells (88.31)

Ligand-Dependent Induction of Noninflammatory Dendritic Cells by Anergic Invariant Nkt Cells Minimizes Autoimmune Inflammation

NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs

Abstract 3966: NK receptors enable TCR-mediated CTL recognition and killing of cancer cells expressing non-mutated tumor-associated antigens

Cbl-b mitigates the responsiveness of naive CD8 + T cells that experience extensive tonic T cell receptor signaling

Largely preserved functionality after the combined loss of NKG2D, NCR1 and CD16 demonstrates the remarkable plasticity of NK cell responsiveness

CARMA3 Deficiency Abrogates G-protein-coupled Receptor Induced NF-κB Activation

Ablation of NK Cell Function During Tumor Growth Favors Type 2-Associated Macrophages, Leading to Suppressed CTL Generation

CD3/CD28 Costimulation-Induced NF-κB Activation is Mediated by Recruitment of Protein Kinase C-θ, Bcl10, and IκB Kinase Β to the Immunological Synapse Through CARMA1

A Requirement for CARMA1 in TCR-induced NF-κB Activation

A Molecular Dissection of Lymphocyte Unresponsiveness Induced by Sustained Calcium Signalling.

CARMA1-mediated NF-kappaB and JNK Activation in Lymphocytes.

Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins

Lipidomic scanning of self-lipids identifies headless antigens for natural killer T cells

Conditional NKT Cell Depletion in Mice Reveals a Negative Feedback Loop That Regulates CTL Cross-Priming